| Product Name | Daprodustat |
|
CAS Number |
960539-70-2 |
|
Purity |
≥99.5% |
|
Total impurity |
≤0.5% |
|
Single impurity |
≤0.2% |
|
Molecular Formula |
C19H27N3O6 |
|
Molecular Weight |
393.43 |
|
Retesting period |
12 months |
|
Storage Condition |
Sealed storage |
|
COA/ROS/MSDS/MOA |
Provided |
Daprodustat is an investigational medication being developed for the treatment of anemia associated with chronic kidney disease. It is a hypoxia-inducible factor prolyl hydroxylase inhibitor that works by stimulating the production of erythropoietin, a hormone that promotes the formation of red blood cells. Daprodustat is taken orally once daily and has shown promising results in clinical trials, demonstrating non-inferiority to the current standard of care, erythropoietin-stimulating agents, while potentially offering certain advantages such as improved iron metabolism and reduced need for intravenous iron supplementation. However, further studies are needed to assess its long-term efficacy and safety. Daprodustat is not currently approved for use by any regulatory authority.
Daprodustat is a highly promising drug that is being developed for the treatment of anemia associated with chronic kidney disease (CKD). Anemia is a serious condition that can cause fatigue, weakness, and other complications, especially in patients with CKD. Daprodustat works by stimulating the production of erythropoietin, a hormone that helps in the production of red blood cells.
This drug has shown significant potential in clinical trials, with promising results in terms of efficacy and safety. It has been shown to increase hemoglobin levels in CKD patients, and reduce the need for blood transfusions. Daprodustat is also, in some cases, effective in reducing the need for erythropoietin-stimulating agents (ESA), which are currently used as the standard treatment for anemia in CKD.
Daprodustat has the potential to improve the quality of life of CKD patients by reducing the symptoms of anemia. It is also a promising therapeutic option for patients who are unresponsive or intolerant to ESA therapy. Moreover, daprodustat has shown good tolerability and safety profile in clinical studies.
The development of daprodustat represents an important advance in the treatment of anemia associated with CKD. It offers new hope to patients who are suffering from this debilitating condition and could potentially reduce the need for blood transfusions and other expensive treatments. With its promising clinical results, daprodustat could become an important tool in the fight against anemia in CKD patient
Hot Tags: daprodustat（gsk1278863）, China daprodustat（gsk1278863） suppliers, factory
